Tag results:
leukocytes
Mesenchymal Cell News
Human Umbilical Cord Mesenchymal Stem Cell-Derived Extracellular Vesicles Attenuate Experimental Autoimmune Encephalomyelitis via Regulating Pro and Anti-Inflammatory Cytokines
[Scientific Reports] Scientists investigated the effect of extracellular vesicles derived from human umbilical cord-MSC on the clinical score and inflammatory/anti-inflammatory cytokines on the EAE mouse model.
Cell Therapy News
Withaferin A Inhibits Lymphocyte Proliferation, Dendritic Cell Maturation In Vitro and Prolongs Islet Allograft Survival
[Scientific Reports] The authors investigated the immunosuppressive and immunomodulation abilities of Withaferin A and its effect on long-term islet allograft survival.
Intestinal Cell News
Implications of Lymphatic Alterations in the Pathogenesis and Treatment of Inflammatory Bowel Disease
[Biomedicine & Pharmacotherapy] The authors examine the implications of lymphatic changes in IBD pathogenesis related to immune cells, gut microbiota, intestinal and mesenteric epithelial barrier integrity, and progression to colorectal cancer.
Human Immunology News
Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC Ligands as Potential Targets for Cancer Immunotherapy
[Oncoimmunology] Researchers investigated the effects of CDK4/6i, abemaciclib and palbociclib, on the immunopeptidome at nontoxic levels in breast cancer cell lines using biochemical identification of HLA ligands followed by network analyses.
Hematopoiesis News
Impact of Prior JAK-Inhibitor Therapy with Ruxolitinib on Outcome after Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Study of the CMWP of EBMT
[Leukemia] The authors studied the impact of pretreatment with JAK1/2 inhibitor ruxolitinib on patient outcome after allogeneic hematopoietic stem cell transplantation.
Immunology of Infectious Disease News
IL-21 and IFNα Therapy Rescues Terminally Differentiated NK Cells and Limits SIV Reservoir in ART-Treated Macaques
[Nature Communications] Scientists reported, using the pathogenic model of antiretroviral therapy-treated, SIV-infected rhesus macaques that sequential interleukin-21 and interferon alpha therapy generated terminally differentiated blood natural killer cells with potent human leukocyte antigen-E-restricted activity in response to SIV envelope peptides.